Sanuwave Health (NASDAQ:SNWV) Issues Earnings Results

Sanuwave Health (NASDAQ:SNWV) announced its quarterly earnings results on Thursday. The company reported ($0.08) EPS for the quarter, missing the consensus estimate of ($0.03) by ($0.05), FiscalAI reports. The firm had revenue of $9.74 million for the quarter, compared to analyst estimates of $11.50 million. Sanuwave Health had a negative return on equity of 450.56% and a net margin of 35.96%.

Sanuwave Health Stock Up 0.5%

Shares of NASDAQ SNWV opened at $6.00 on Friday. The stock has a fifty day moving average price of $9.91 and a 200 day moving average price of $17.08. The company has a current ratio of 1.31, a quick ratio of 0.99 and a debt-to-equity ratio of 8.15. Sanuwave Health has a 12-month low of $5.77 and a 12-month high of $46.58. The company has a market cap of $51.60 million, a P/E ratio of 18.18 and a beta of 1.48.

Institutional Investors Weigh In On Sanuwave Health

Large investors have recently modified their holdings of the stock. Huntleigh Advisors Inc. acquired a new position in shares of Sanuwave Health during the fourth quarter worth $998,000. Corient Private Wealth LLC acquired a new stake in Sanuwave Health during the 4th quarter valued at $257,000. Wells Fargo & Company MN increased its stake in Sanuwave Health by 88.8% during the 4th quarter. Wells Fargo & Company MN now owns 8,137 shares of the company’s stock worth $243,000 after buying an additional 3,828 shares during the period. HRT Financial LP purchased a new stake in Sanuwave Health during the 4th quarter worth $205,000. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. acquired a new position in Sanuwave Health in the 2nd quarter worth $126,000. Institutional investors and hedge funds own 42.53% of the company’s stock.

Analysts Set New Price Targets

Separately, Weiss Ratings reissued a “hold (c-)” rating on shares of Sanuwave Health in a research report on Wednesday, June 24th. One research analyst has rated the stock with a Strong Buy rating, one has assigned a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, Sanuwave Health currently has an average rating of “Moderate Buy” and an average price target of $51.00.

Sanuwave Health Company Profile

Sanuwave Health, Inc is a medical technology company specializing in the development and commercialization of non-invasive acoustic wave therapies designed to stimulate tissue regeneration and accelerate healing. The company’s proprietary Extracorporeal Pulse Activated Technology (EPAT) delivers focused acoustic pressure waves to injured or chronic wound sites, activating the body’s natural repair mechanisms. Sanuwave’s primary therapeutic areas include advanced wound care for diabetic and venous ulcers, as well as orthopedic and musculoskeletal conditions.

The company’s lead product, the dermaPACE® system, holds clearance from the U.S.